Table 3.
Patients with positive interpretation on SOC-BMRI or AB-MRI
| Patient No. | Prior MRI Exams (n) | SOC BI-RADS | Outcome | AB-MRI BI-RADS | Lesion Typea | MRI-Guided Biopsy | Surgical Pathology | |||
|---|---|---|---|---|---|---|---|---|---|---|
| AB1 | AB2 | AB3 | AB4 | |||||||
| 10 | 4 | 1/2 | TN | 4 | 4 | 4 | 1/2 | Mass | ||
| 11 | 7 | 1/2 | TN | 4 | 4 | 1/2 | NME | |||
| 26 | 1 | 1/2 | TN | 4 | 4 | 1/2 | Mass | |||
| 27 | 0 | 4 | FP | 1/2 | 1/2 | 1/2 | NME | FCC, IDP | ||
| 30 | 0 | 1/2 | TN | 4 | 4 | 1/2 | Mass | |||
| 37 | 1 | 1/2 | TN | 4 | 4 | 1/2 | Mass | |||
| 39 | 9 | 1/2 | TN | 4 | 4 | 1/2 | Mass | |||
| 41 | 8 | 1/2 | TN | 4 | 1/2 | 1/2 | ||||
| 49 | 5 | 1/2 | TN | 4 | 4 | 1/2 | NME | |||
| 53 | 0 | 4 | FP | 4 | 1/2 | 1/2 | Mass | FCC, IDP | ||
| 62 | 2 | 1/2 | TN | 1/2 | 4 | 1/2 | NME | |||
| 64 | 5 | 1/2 | TN | 4 | 1/2 | 1/2 | ||||
| 69 | 0 | 4 | FP | 1/2 | 1/2 | 1/2 | NME | ALH, CCC, stromal fibrosis | ||
| 70b | 0 | 0 | FP | 1/2 | 1/2 | 1/2 | Mass | |||
| 73 | 1 | 1/2 | TN | 4 | 4 | 1/2 | Mass | |||
| 78c (lesion 1) | 8 | 4 | TP | 4 | 4 | 4 | 4 | NME (right) | DCIS low grade | ADH (cribriform pattern), ALH |
| 78c (lesion 2) | 8 | 4 | FP | 4 | 4 | 4 | 4 | NME (left) | ADH, single focus | |
| 79 | 3 | 1/2 | TN | 4 | 4 | 1/2 | Mass | |||
| 93 | 3 | 1/2 | TN | 4 | 4 | 4 | 1/2 | NME and mass | ||
| 94 | 0 | 3 | TN | 4 | 4 | 1/2 | Mass | |||
| 101 | 9 | 1/2 | TN | 4 | 4 | 1/2 | Mass | |||
| 103 | 9 | 1/2 | TN | 4 | 4 | 4 | 1/2 | Focus | ||
| 109 | 0 | 1/2 | TN | 4 | 4 | 4 | NME | |||
| 122 | 4 | 1/2 | TN | 4 | 1/2 | 1/2 | ||||
| 125d | 3 | 4 | FP | 4 | 4 | 4 | 4 | NME | ADH | Benign |
SOC: standard of care; BMRI: breast MRI; AB-MRI: abbreviated-breast MRI; BMRI: breast MRI; AB1: evaluation of maximum intensity projective images, including color-coded map; AB2: evaluation of dynamic contrast-enhanced images; AB3: evaluation of T2-weighted and fat-only images; AB4: non-blinded comparison performed only if AB3 was BI-RADS 4 and prior MRI exams were available; TN: true negative; FP: false positive; TP: true positive; NME: nonmass enhancement; FCC: fibrocystic changes; IDP: intraductal papilloma; ALH: atypical lobular hyperplasia; CCC: columnar cell change: DCIS: ductal carcinoma in situ; ADH: atypical ductal hyperplasia.
Lesions were not characterized if they were visualized only on maximum intensity projections.
Patient no. 70 underwent a second look for a circumscribed oval mass with dark internal septations. The second look determined that the mass was benign. A follow-up BMRI was performed 1 year later and had a benign result.
Patient no. 78 underwent a right mastectomy, showing atypia insufficient to meet DCIS criteria but morphologically similar to DCIS in the MR biopsy. She has undergone benign imaging follow -up with mammogram and ultrasound for the contralateral (left) breast.
Patient no. 125 underwent bilateral skin-sparing mastectomies with no evidence of atypia or carcinoma.